AVEO Oncology Articles
Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders
27 March 2013
AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar
14 February 2013
AVEO and Astellas file NDA for tivozanib in kidney cancer
2 October 2012
Showing 1-4 of 4 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
